SCHEMBL5795904

SCHEMBL5795904

Cc1cc(CCl)cc(C)c1OCc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.46
MAPT P10636 1/20 0.46
MAPK1 P28482 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
HTT P42858 3/20 0.44
HPGD P15428 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
MEN1 O00255 1/20 0.44
ALDH1A1 P00352 1/20 0.44
KMT2A Q03164 1/20 0.44
LMNA P02545 2/20 0.44
POLB P06746 1/20 0.44
GAA P10253 1/20 0.44
FFAR4 Q5NUL3 1/20 0.43
GLRA1 P23415 1/20 0.43
PTPN1 P18031 1/20 0.43
HTR1A P08908 1/20 0.43
ADRA1D P25100 1/20 0.43
ADRA1A P35348 1/20 0.43
ADRA1B P35368 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19532377 0.90 MAPT (0.49) L3MBTL1MAPTMAPK1TDP1HTT
SCHEMBL5793118 0.86 FFAR4 (0.47) L3MBTL1MAPTMAPK1TDP1HPGD
SCHEMBL14291457 0.84 TSHR (0.49) L3MBTL1MAPTMAPK1TDP1HTT
SCHEMBL10481838 0.83 MAPT (0.50) L3MBTL1MAPTMAPK1TDP1HTT
SCHEMBL24372040 0.82 MAOB (0.51) L3MBTL1MAPTMAPK1TDP1HTT
SCHEMBL1143540 0.81 MAOB (0.53) L3MBTL1MAPTMAPK1TDP1SMN1; SMN2
SCHEMBL7535983 0.81 LMNA (0.53) L3MBTL1MAPTMAPK1TDP1HPGD
SCHEMBL348875 0.80 MEN1 (0.55) L3MBTL1MAPTMAPK1TDP1HPGD
SCHEMBL8555303 0.80 KDM1A (0.49) L3MBTL1MAPTMAPK1TDP1HTT
SCHEMBL5690860 0.80 MAPT (0.47) L3MBTL1MAPTMAPK1TDP1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060079696-A1 Substituted compounds derived from N-(benzyl)phenylacetamide, preparation and uses GENFIT (FR) 2006-04-13 US disclosed
WO-2006035157-A2 SUBSTITUTED N-(BENZYL)PHENYLACETAMIDE DERIVATIVE COMPOUNDS, PREPARATION METHOD THEREOF AND USES OF SAME AS PPAR LIGANDS IN THE TREATMENT OF LIPID AND/OR GLUCIDIC DISORDERS GENFIT (FR) 2006-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079696-A1 Substituted compounds derived from N-(benzyl)phenylacetamide, preparation and uses AADAC, NAT1, PARN L3MBTL1 2320/4885MAPT 1172/4885MAPK1 3624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.